Bristol Myers (BMY)’ Massachusetts facility boosted drug production volume for clinical and commercial use by about 40% with AI, The New York Times’ Farah Stockman reports. “We are able to now intervene in the batches during the manufacturing process and not have to wait until we get to the end,” said Karin Shanahan, executive vice president, chief supply chain and operations officer for the company. These innovations have helped stabilize production of Orencia, a drug that treats autoimmune conditions such as rheumatoid arthritis using cells that are extremely difficult to grow, according to the report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- FDA blocked publication of studies showing Covid vaccine safe, NYT says
- Trump Trade: Microsoft, Google agree to U.S. security reviews of AI models
- Analyst Maintains Hold on Bristol-Myers Squibb, Keeps Price Target Unchanged at $61 Amid Pipeline Uncertainty
- Bristol Myers price target raised to $66 from $64 at Citi
- Bristol-Myers Squibb Signals Confident Path After Q1 Call